Revenue Estimates Analysis Of Histogenics Corporation (HSGX)


Histogenics Corporation (HSGX) will report its next earnings on Aug 09 BMO. The company reported the earnings of $-0.13/Share in the last quarter where the estimated EPS by analysts was $-0.23/share. The difference between the expected and actual EPS was $0.1/share, which represents an Earnings surprise of 43.5%.

Many analysts are providing their Estimated Earnings analysis for Histogenics Corporation and for the current quarter 6 analysts have projected that the stock could give an Average Earnings estimate of $-0.19/share. These analysts have also projected a Low Estimate of $-0.26/share and a High Estimate of $-0.14/share.

Some buy side analysts are also providing their Analysis on Histogenics Corporation, where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Histogenics Corporation might touch $5 high while the Average Price Target and Low price Target is $3.2 and $1.5 respectively.

The Relative Volume of the company is 49.46 and Average Volume (3 months) is 921.13 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -173.6%. The Return on Equity (ROE) value stands at 184.5%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, Histogenics Corporation currently shows a Weekly Performance of 78.92%, where Monthly Performance is 31.58%, Quarterly performance is -59.68%, 6 Months performance is -64.29% and yearly performance percentage is -51.22%. Year to Date performance value (YTD perf) value is -51.22%. The Stock currently has a Weekly Volatility of 33.90% and Monthly Volatility of 17.73%.